MLND
Income statement / Annual
Last year (2024), Millendo Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Millendo Therapeutics, Inc.'s net income was -$41.84 M.
See Millendo Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
| Period Ended |
12/31/2024 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$295.00 K |
$653.00 K |
$277.00 K |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$790.00 K
|
$5.40 M
|
$2.25 M
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$495.00 K
|
-$4.75 M
|
-$1.97 M
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
-1.68
|
-7.27
|
-7.12
|
0
|
0
|
0
|
| Research and Development Expenses |
$28.48 M
|
$20.37 M
|
$27.84 M
|
$14.43 M
|
$18.34 M
|
$21.64 M
|
$18.43 M
|
$21.78 M
|
$15.80 M
|
$6.32 M
|
| General & Administrative Expenses |
$13.55 M
|
$15.60 M
|
$17.56 M
|
$12.45 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$13.33 M
|
$7.21 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$13.55 M
|
$15.60 M
|
$17.56 M
|
$12.45 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$13.33 M
|
$7.21 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$27.74 M
|
$49.22 M
|
$51.59 M
|
$26.15 M
|
$0.00
|
$0.00
|
| Operating Expenses |
$42.03 M
|
$35.97 M
|
$45.40 M
|
$26.87 M
|
$46.08 M
|
$70.86 M
|
$70.03 M
|
$47.93 M
|
$29.13 M
|
$13.53 M
|
| Cost And Expenses |
$0.00
|
$35.97 M
|
$45.40 M
|
$26.87 M
|
$46.87 M
|
$76.27 M
|
$72.28 M
|
$47.93 M
|
$29.13 M
|
$13.53 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
-$1.32 M
|
$0.00
|
-$1.04 M
|
$134.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$1.10 M
|
$1.05 M
|
$32.00 K
|
$1.65 M
|
$2.24 M
|
$1.29 M
|
$450.00 K
|
$231.00 K
|
$93.00 K
|
| EBITDA |
$0.00 |
-$35.30 M |
-$44.55 M |
-$27.03 M |
-$49.26 M |
-$79.82 M |
-$71.86 M |
-$49.07 M |
-$28.81 M |
-$13.42 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
-166.98
|
-122.24
|
-259.42
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
-157.88
|
-115.79
|
-259.92
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$0.00
|
-$434.00 K
|
$831.00 K
|
-$303.00 K
|
-$4.33 M
|
-$6.45 M
|
-$1.15 M
|
-$1.59 M
|
$90.00 K
|
$19.00 K
|
| Income Before Tax |
-$41.84 M
|
-$36.41 M
|
-$44.57 M
|
-$27.18 M
|
-$50.91 M
|
-$82.06 M
|
-$73.14 M
|
-$49.52 M
|
-$29.04 M
|
-$13.51 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
-172.57
|
-125.66
|
-264.06
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
-$169.00 K
|
$67.00 K
|
$201.00 K
|
$75.00 K
|
$0.00
|
$90.00 K
|
$19.00 K
|
| Net Income |
-$41.84 M
|
-$36.41 M
|
-$44.57 M
|
-$27.19 M
|
-$50.98 M
|
-$82.26 M
|
-$73.22 M
|
-$49.52 M
|
-$29.04 M
|
-$13.51 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
-172.8
|
-125.97
|
-264.33
|
0
|
0
|
0
|
| EPS |
-1.5 |
-28.95 |
-48.77 |
-263.65 |
-321.49 |
-575.72 |
-608.24 |
-491.98 |
-404.39 |
-523.2 |
| EPS Diluted |
-1.5 |
-28.95 |
-48.77 |
-263.65 |
-321.49 |
-575.72 |
-608.24 |
-491.98 |
-404.39 |
-523.2 |
| Weighted Average Shares Out |
$27.90 M
|
$1.26 M
|
$913.79 K
|
$103.14 K
|
$158.56 K
|
$142.88 K
|
$120.38 K
|
$100.65 K
|
$71.82 K
|
$25.82 K
|
| Weighted Average Shares Out Diluted |
$27.90 M
|
$1.26 M
|
$913.79 K
|
$103.14 K
|
$158.56 K
|
$142.88 K
|
$120.38 K
|
$100.65 K
|
$71.82 K
|
$25.82 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
